Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cantor Fitzgerald
Argus Health
Harvard Business School
Accenture
Federal Trade Commission
Queensland Health
Johnson and Johnson
Fuji
Merck

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,173,851

« Back to Dashboard

Which drugs does patent 9,173,851 protect, and when does it expire?


Patent 9,173,851 protects PROCYSBI and is included in one NDA.

This patent has seventeen patent family members in sixteen countries.

Summary for Patent: 9,173,851

Title:Delayed release cysteamine bead formulation, and methods of making and using same
Abstract: An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
Inventor(s): Powell; Kathlene (Cary, NC), Muttavarapu; Ramesh (Durham, NC)
Assignee: RAPTOR PHARMACEUTICALS INC. (Novato, CA)
Application Number:14/751,639
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-001Apr 30, 2013RXYesNo► Subscribe► SubscribeY
Horizon Pharma Usa
PROCYSBI
cysteamine bitartrate
CAPSULE, DELAYED RELEASE;ORAL203389-002Apr 30, 2013RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,173,851

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,233,077Delayed release cysteamine bead formulation, and methods of making and using same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,173,851

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina096628► Subscribe
Australia2014281702► Subscribe
Canada2914770► Subscribe
Canada2938644► Subscribe
Chile2015003662► Subscribe
China105492000► Subscribe
Cuba20150178► Subscribe
Eurasian Patent Organization201690036► Subscribe
European Patent Office3010491► Subscribe
Hong Kong1218066► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
QuintilesIMS
Teva
Dow
Citi
Covington
Deloitte
Chinese Patent Office
UBS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot